Browsing Clinical Studies by author "Cunningham, David"
Now showing items 41-60 of 80
-
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Townsend, W; Hiddemann, W; Buske, C; Cartron, G; Cunningham, D; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-07-01)The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). ... -
Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma.
Mohamed, AA; Gordon, A; Cartwright, E; Cunningham, D (2022-01-24)Oesophago-gastric adenocarcinoma remains a leading cause of cancer-related morbidity and mortality worldwide. Although there has been an enormous progress in the multimodality management of resectable oesophago-gastric ... -
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl, A; Cunningham, D; Counsell, N; Hawkes, EA; Qian, W; et al. (2017-07)Background There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized ... -
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Tait, D; et al. (2016-08)Background EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC).Design We pooled individual patient ... -
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný, M; Avigdor, A; McKinney, MS; Paneesha, S; Wahlin, BE; et al. (ELSEVIER, 2023-09-01)BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT ... -
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials.
Athauda, A; Nankivell, M; Langer, R; Pritchard, S; Langley, RE; et al. (SPRINGERNATURE, 2023-06-15)BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following ... -
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy, M; Chavez, JC; Avivi, I; Larouche, J-F; Wannesson, L; et al. (American Society of Hematology, 2022-07-15)Here we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy versus standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma ... -
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Pugh, SA; Bowers, M; Ball, A; Falk, S; Finch-Jones, M; et al. (2016-08)Background The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further ... -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham, D; Stenning, SP; Smyth, EC; Okines, AF; Allum, WH; et al. (2017-03)Background Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients ... -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply.
Smyth, EC; Allum, WH; Rowley, S; Langley, RE; Cunningham, D (2017-05) -
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh, P; Hanson, R; Titman, A; Lancaster, G; Plumpton, C; et al. (2018-02)Background Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of ... -
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth, E; Zhang, S; Cunningham, D; Wotherspoon, A; Soong, R; et al. (2017-12)Purpose: Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the effect of polymorphisms in drug metabolism and DNA repair genes on pathologic response rates, survival, and toxicity for patients ... -
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins, GP; Clevenger, TN; Burke, KA; Yang, B; MacDonald, A; et al. (TAYLOR & FRANCIS LTD, 2021-07-15)In a phase 1b study of acalabrutinib (a covalent Bruton tyrosine kinase (BTK) inhibitor) in combination with vistusertib (a dual mTORC1/2 inhibitor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), ... -
Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma
Dreyling, MH; Morschhauser, F; Bouabdallah, K; Cunningham, D; Bron, D; et al. (2017-09) -
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling, M; Morschhauser, F; Bouabdallah, K; Bron, D; Cunningham, D; et al. (2017-09)Background Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms.Patients and methods This phase II study evaluated the response rate of copanlisib ... -
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Shah, MA; Bodoky, G; Starodub, A; Cunningham, D; Yip, D; et al.Purpose Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified ... -
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani, F; Morano, F; Cunningham, D; Baratelli, C; Kalaitzaki, E; et al. (2017-04)Background Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have ... -
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
Grenader, T; Waddell, T; Peckitt, C; Oates, J; Starling, N; et al. (2016-04) -
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi, Q; Schmitz, N; Ou, F-S; Dixon, JG; Cunningham, D; et al. (2018-09)Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed ... -
Quality of life, long-term survivors and long-term outcome from the ABC-02 study.
Bridgewater, J; Lopes, A; Palmer, D; Cunningham, D; Anthoney, A; et al. (2016-04)Background The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). ...